Literature DB >> 34465464

Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study).

Parveen K Garg1, Faye L Norby2, Wendy Wang3, Darshan Krishnappa4, Elsayed Z Soliman5, Pamela L Lutsey3, Elizabeth Selvin6, Christie M Ballantyne7, Alvaro Alonso8, Lin Y Chen4.   

Abstract

We evaluated the association of longitudinal changes in circulating levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT) with the burden of arrhythmias as captured by 2-week ambulatory ECG monitoring. This study included 1,930 Atherosclerosis Risk in Communities Study participants who wore a leadless, ambulatory ECG monitor (Zio XT Patch) at visit 6 (2016 to 2017) and had cardiac biomarkers measured at visit 6 and visit 4 (median of 19 years earlier). The mean age of participants at V6 was 79 ± 5 years, 41% were men, and 22% were black. Adjusting for demographics, body mass index, smoking, diabetes, hypertension, stroke, left ventricular mass, cardiac medications, patch wear time, visit 4 levels of NT-proBNP and hs-cTnT, and relative change in hs-cTnT, each log-transformed unit relative increase in NT-proBNP was associated with a higher likelihood of nonsustained ventricular tachycardia (odds ratio 1.29, 95% confidence interval [CI] 1.12 to 1.48), a higher number of daily atrial tachycardia episodes (geometric mean ratio [GMR] 1.16, 95% CI 1.10 to 1.21), and a higher daily ectopic burden (premature ventricular contractions -GMR 1.42, 95% CI 1.25 to 1.62; premature atrial contractions -GMR 1.40, 95% CI 1.25 to 1.57). In fully adjusted analyses, each log-transformed unit relative increase in hs-cTnT was only found to be weakly associated with a higher daily premature ventricular contraction burden (GMR 1.31, 95% CI 1.01 to 1.70). In conclusion, longitudinal change in NT-proBNP was associated with an increased atrial and ventricular arrhythmia burden.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34465464      PMCID: PMC8497411          DOI: 10.1016/j.amjcard.2021.07.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Tarantula peptide inhibits atrial fibrillation.

Authors:  F Bode; F Sachs; M R Franz
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

Review 2.  Management of premature ventricular complexes.

Authors:  Albert K Chan; Mary L Dohrmann
Journal:  Mo Med       Date:  2010 Jan-Feb

3.  Predictors of atrial ectopy and their relationship to atrial fibrillation risk.

Authors:  Tuomas Kerola; Thomas A Dewland; Eric Vittinghoff; Susan R Heckbert; Phyllis K Stein; Gregory M Marcus
Journal:  Europace       Date:  2019-06-01       Impact factor: 5.214

4.  N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Authors:  Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Per R Hildebrandt
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

5.  Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.

Authors:  Aharon Medina; Arthur J Moss; Scott McNitt; Wojciech Zareba; Paul J Wang; Ilan Goldenberg
Journal:  Heart Rhythm       Date:  2015-12-25       Impact factor: 6.343

6.  Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.

Authors:  Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

7.  Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis.

Authors:  Satoru Suzuki; Michihiro Yoshimura; Masafumi Nakayama; Yuji Mizuno; Eisaku Harada; Teruhiko Ito; Shota Nakamura; Koji Abe; Megumi Yamamuro; Tomohiro Sakamoto; Yoshihiko Saito; Kazuwa Nakao; Hirofumi Yasue; Hisao Ogawa
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

8.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

9.  Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure.

Authors:  C Haug; A Metzele; M Kochs; V Hombach; A Grünert
Journal:  Clin Cardiol       Date:  1993-07       Impact factor: 2.882

10.  Biomarkers of cardiovascular injury and stress are associated with increased frequency of ventricular ectopy: a population-based study.

Authors:  Julia Brox Skranes; Gunnar Einvik; Silje Kjeka Namtvedt; Anna Randby; Harald Hrubos-Strøm; Jon Brynildsen; Tor-Arne Hagve; Virend K Somers; Helge Røsjø; Torbjørn Omland
Journal:  BMC Cardiovasc Disord       Date:  2016-11-22       Impact factor: 2.298

View more
  1 in total

1.  Blood-Based Biomarkers to Search for Atrial Fibrillation in High-Risk Asymptomatic Individuals and Cryptogenic Stroke Patients.

Authors:  Elena Palà; Alejandro Bustamante; Jorge Pagola; Jesus Juega; Jaume Francisco-Pascual; Anna Penalba; Maite Rodriguez; Mercedes De Lera Alfonso; Juan F Arenillas; Juan Antonio Cabezas; Soledad Pérez-Sánchez; Francisco Moniche; Reyes de Torres; Teresa González-Alujas; Josep Lluís Clúa-Espuny; Juan Ballesta-Ors; Domingo Ribas; Juan Acosta; Alonso Pedrote; Felipe Gonzalez-Loyola; Delicia Gentile Lorente; Miguel Ángel Muñoz; Carlos A Molina; Joan Montaner
Journal:  Front Cardiovasc Med       Date:  2022-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.